Detail akcie bioXXmed Br online

Business Summary: bioXXmed AG is a Germany-based holding company that invests in biotechnological or medical technology companies with equity or borrowed capital. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, bioXXmed AG revenues decreased 80% to EUR3K. Net loss decreased 95% to EUR997K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Write-Off on Financials decrease of 99% to EUR129K (expense), Other Operating Revenue increase from EUR3K to EUR31K (income), Amortization/Depreciation remaining flat at EUR0K.